Mission Bio develops single-cell MRD assay

Personalis, Tempus collaborate to commercialize MRD test

Personalis Inc. announced the commencement of commercialization efforts by Tempus for NeXT Personal, Personalis’ ultra-sensitive, whole genome-based liquid biopsy assay for detection of minimal residual disease and recurrence in cancer.

May 31, 2024

Vol.50 No.22

Clinical Roundup

Orca-T improves AML survival in phase Ib trial subgroup

Orca Bio will present new data at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago.

May 24, 2024

Vol.50 No.21

Clinical Roundup

Older adults with aggressive blood cancer are responsive to treatment and show prolonged survival

Standard of care treatment for acute myeloid leukemia is safe and effective for adults over 80, according to a study published in Blood Neoplasia. For roughly a quarter of patients, this treatment can durably prolong survival.

May 17, 2024

Vol.50 No.20

Clinical Roundup

Lower MRD prior to HCT associated with better outcomes in FLT3-ITD AML

Patients in remission after being treated for a high-risk blood cancer are likely to have better outcomes if no trace of the cancer is detectable before the patients receive donor blood cells.

May 03, 2024

Vol.50 No.18

Drugs & Targets

Tempus develops MRD assay for colorectal cancer

Tempus has added a novel MRD assay, xM, to its testing solutions.

January 26, 2024

Vol.50 No.04

Clinical Roundup

Vitamin C, D supplements led to fewer complications in AML, no OS benefit

Patients with acute myeloid leukemia who received vitamin C and D supplements while undergoing intensive chemotherapy had lower rates of complications, such as infections, bleeding, and inflammation, when compared with similar, previously treated patients who did not receive these supplements.

September 15, 2023

Vol.49 No.34

Mission Bio develops single-cell MRD assay

YOU MAY BE INTERESTED IN

Personalis, Tempus collaborate to commercialize MRD test

Orca-T improves AML survival in phase Ib trial subgroup

Older adults with aggressive blood cancer are responsive to treatment and show prolonged survival

Lower MRD prior to HCT associated with better outcomes in FLT3-ITD AML

Tempus develops MRD assay for colorectal cancer

Vitamin C, D supplements led to fewer complications in AML, no OS benefit

Renew today!

Subscriber content

Login